SEC Filing Summary: Xenomics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Xenomics, Inc. on November 7, 2006. The report discloses a significant corporate governance event regarding the departure of a principal officer. Note: The input metadata references "Cardiff Oncology, Inc.", but the filing text explicitly identifies the registrant as "Xenomics, Inc."
Key Financial Metrics
The filing text does not provide any financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is strictly limited to the disclosure of executive personnel changes.
Material Changes
The primary material change reported is the voluntary resignation of Dr. L. David Tomei. Effective November 7, 2006, Dr. Tomei stepped down from his roles as Chief Executive Officer and Co-Chairman of Xenomics, Inc.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to notify the market of the executive departure.
Key Facts for Investor Verification
- Verify the appointment of a new Chief Executive Officer and Co-Chairman to replace Dr. L. David Tomei.
- Confirm whether Dr. Tomei's resignation impacts ongoing clinical trials or strategic partnerships.
- Check for subsequent filings regarding the composition of the Board of Directors following the Co-Chairman vacancy.
- Clarify the discrepancy between the metadata company name (Cardiff Oncology) and the filing registrant (Xenomics).